The News
Does the stock exchange still properly serve our economy?
27/08/2007
Several facts cast serious doubt on the utility of the stock exchange to our economy at the present time.
First, companies listed on Euronext Paris raised a total of 37.5 billion euro in 2006. However, the CAC 40 companies alone (a subset of Euronext) paid out a total of 39 billion euro to their shareholders thus resulting in a deficit of at least 1.5 billion euro. The overall picture in 2004 and in 2005 was similar. One needs to go back to 2003 to find a situation where the total amount of capital raised (31.6 billion euro) exceeded dividends and share redemptions (22 billion euro). Listed companies are no longer being financed; instead they are getting poorer.
Second, a recent Ernst & Young study on the evolution of the NASDAQ shows that investors are disaffected with technology stocks. In particular, from 2001 to 2006, the average valuation of a technology company at the time of its listing represented only 39% of the average valuation of companies first listed back in the 1992-1996 time period (which was well before the 1999-2000 boom). The NASDAQ, the specialised US stock exchange which financed all the American technology giants, from Intel to Microsoft, from Cisco to Oracle, is in a deadlock: public listings no longer compensate for the risk taken by the investors. And yet the economy is booming and capital is readily available.
Third, in 2005, the average holding period of shares by American mutual funds fell to its historical record of only 10 months.
What is the common root of those three facts? Quite simply it is the stark reality that long-term investment is no longer profitable. Even though they only have a small percentage of capital, hedge funds manipulate market prices and set the agenda: mergers, acquisitions, rapid distributions of assets through bonus dividends and share redemptions. The same policy is applied by a large number of LBO funds through company takeovers by delisting or in the private sector, through massive debt financing, rapid restructuring, distributions of assets, cost cutting in order to quickly improve profitability and sales to other LBO funds. What is the level of risk attached to such operations? Almost none because the targeted companies are established enterprises with records of sustained profitability. The only risk is a self-induced risk through debt leverage at the burden of the target. When significant profits, quick cash distributions and limited risk are available, why would anyone invest long-term?
We are clearly facing an anomaly in the system: it is simply not possible to quickly earn money with no risk over an extended period of time. As in the past, the system will correct itself. But one may ask when and at what cost to our economy.
The price we are paying for this is already high. We will only manage to achieve the universally sought after society of “innovation and technology” if long-term investments are revitalised. We will only create technological champions providing increased levels of future employment if there is a stock exchange with the capacity to build on the investments made by those who assumed the start-up risk. Our high performance SMEs which are so dearly valued by our governments will only conquer exportation markets if they can find support from the stock exchange. Similarly, the best family-run companies will remain as targets for LBO funds for so long as capital transmissions cannot be done effectively through the stock exchange. The key point to keep in mind is that the exchange is the only medium which provides the means for genuine economic growth based on long-term interests, i.e. capital contributions, cash flow for initial shareholders, the possibility of hiring the best managers, and, most importantly, independence.
What should be done then to make sure that the exchange fulfils its original role of being an engine for the economy? For starters, we should alert our institutional investors (insurance companies, pension funds and mutual funds) of the need for them to make sure that a large part of their investments is reserved for long-term investments. At the moment, those institutional investors are actually financing LBOs and hedge funds. By not participating in shareholders meetings, the institutional investors give hedge funds the openings they need to pursue their aggressive strategy. Furthermore, those institutional investors are shifting any resources they have from long-term to short-term investment.
What else can be done? Certainly tax laws should be modified to address the current problem. It would be useful to seriously consider promoting long-term investments, in particular as part of initial public offerings, by granting advantageous tax treatment to such investments, both for individuals and collective investment vehicles. However, at this stage, the most important measure is establishing proper taxation for hedge and LBO funds. How can we today justify exempting capital gains of those funds and allowing interest on debt financing be tax deductible, thereby leading to an additional return on profits which itself distorts competition?
By applying proper taxation to these funds, we would act equitably and at the same time we would reinstall a basis for a genuine and fair choice to be made between short-term or long-term investments.
Let’s face the truth: we are currently weakening our best companies at the very moment when they need support to combat fierce competition from Japan, Korea, China, and India. All of those countries have developed highly ambitious and efficient strategies with an emphasis on long term interests while we allow short term interests to eat away at our economy.
Jean-Bernard Schmidt
2007
- 04/01/2007
-
08/01/2007
Movetis NV conclut un premier tour de financement de 49 millions d'euros
- 08/01/2007
- 09/01/2007
-
08/01/2007
UPEK is named CES Best of Innovations 2007 Design and Engineering Award Winner
-
16/01/2007
FOVEA Pharmaceuticals SA obtains Exclusive Worldwide Rights on RdCVF Protein Therapy
-
18/01/2007
CoreValve announces the appointment of Dolf Meewis as Vice President of International Sales
-
22/01/2007
INSIDE Launches High Performance MicroPass(R) L4-2G Contactless Platform
- 19/01/2007
-
15/01/2007
Varioptic and Creative Sensor Announce Liquid Lens Mass Production in China
-
24/01/2007
Addex starts Phase IIa Proof of Concept Study on ADX10061 for Smoking Cessation
- 31/01/2007
- 31/01/2007
- 31/01/2007
-
02/02/2007
Lenovo Mobile Selects Esmertec’s Jbed Software Solution to Power Major Platforms for Mobile Handsets
-
28/01/2007
UPEK Delivers First Biometric Security Software Solution for Windows Vista Operating System
- 02/02/2007
-
06/02/2007
Innate Pharma announces operating revenue of 8.4 million euros in 2006 and updates on its finances
-
06/02/2007
CPI Card Group Adopts INSIDE's Next-Generation MicroPass L4-2G Contactless Platform
- 08/02/2007
-
13/02/2007
Discover® Network certifies Inside Contactless chip for contactless payment cards & devices
- 14/02/2007
-
28/02/2007
IDM Pharma Announces the Completion of Enrollment in Two Phase II Trials of Uvidem(R) in Melanoma
- 02/03/2007
-
08/03/2007
7TM Pharma advances the next first-in-class obesity compound into clinical development
- 08/03/2007
-
19/02/2007
Inside Contactless nominated for Performance AWARD Les Echos
-
08/03/2007
Streamezzo expands executive team with general manager for EMEA
- 13/03/2007
- 20/03/2007
- 26/03/2007
- 28/03/2007
- 29/03/2007
- 26/03/2007
-
03/04/2007
EmailVision : Forte progression du Résultat d'Exploitation au 2nd semestre 2006
- 03/04/2007
-
30/03/2007
Inside Extends Smart Card Alliance Involvement Within the Leadership Council
- 05/04/2007
- 10/04/2007
- 10/04/2007
- 17/04/2007
- 17/04/2007
- 08/03/2007
- 20/04/2007
-
20/04/2007
Addex reports positive results in Phase IIa clinical trial with ADX10059 in Migraine
-
26/04/2007
E-Mail Vision Forte croissance de l’activité au 1er trimestre 2007
-
26/04/2007
Innate Pharma S.A. announced two additional clinical trials for its IPH 1101 drug candidate
- 02/05/2007
- 03/05/2007
-
16/05/2007
ReVolt Technology and Phonak AG to Develop Rechargeable Zinc-air Battery Technology for Hearing Aids
- 16/05/2007
- 17/05/2007
-
30/05/2007
Esmertec Announces Robust Operational Performance in Q1 2007
- 05/06/2007
- 04/06/2007
- 01/06/2007
-
06/06/2007
Inside's Micropass reaches new milestone with 20 million units sold
- 07/06/2007
-
06/06/2007
MOVETIS Announces Start of A Phase IIa trial for M0002 in Ascites
- 07/06/2007
-
07/06/2007
NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board
- 12/06/2007
-
23/05/2007
Streamezzo closes its second round of financing with investment from Qualcomm Ventures
- 10/06/2007
- 18/06/2007
-
18/06/2007
Ablynx identifies novel nanobodies® achieving second milestone in Procter & Gamble collaboration
-
21/06/2007
Innate Pharma has received approval for its phase II trial with IPH 1101 in HCV in France
- 21/06/2007
-
25/06/2007
Innate Pharma annonce un nouvel essai clinique avec IPH 2101 (NN 1975), le premier sous U.S ind
- 25/06/2007
- 27/06/2007
- 27/06/2007
-
29/06/2007
Frost & Sullivan Bestows its 2007 global contactless innovation & advancement award
-
02/07/2007
Ablynx announces interim results of first NANOBODY® Phase I study of ALX-0081 (anti-VWF)
- 06/07/2007
-
03/07/2007
Diatos Completes a Series D €9.4 Million Private Financing Round
-
10/07/2007
Sensitive Object and Tyco Electronics' Elo TouchSystems Business Sign License Agreement
- 09/05/2007
- 25/07/2007
-
25/07/2007
Addex Pharmaceuticals : Résultats Financiers du Premier Semestre 2007
-
30/05/2007
CTS International acquires Planet EV product line from Ericsson
- 05/07/2007
- 14/08/2007
- 06/08/2007
- 16/08/2007
- 24/07/2007
- 20/07/2007
-
24/07/2007
CoreValve named to Red Herring magazine’s ‘top 100’ North American private companies
-
22/08/2007
IBM Acquires WebDialogs to Expand Web Conferencing Capabilities in Industry-Leading Lotus Sametime
- 27/08/2007
-
27/08/2007
Does the stock exchange still properly serve our economy?
-
23/08/2007
Software and IT Executives Learn Growth and Exit Strategies at WFS' Fourth Annual London Conference
-
30/08/2007
Stentys appoints Hikmat Hojeibane as Chief Technology Officer
- 06/09/2007
- 07/09/2007
-
17/09/2007
DBV Technologies expands management team and moves to new facilities in Paris
-
18/09/2007
Inside chosen for world's first NFC-enabled M-payment rollout
-
19/09/2007
Sofinnova Partners Names Chika Yoshinaga Vice President, Asia
-
19/09/2007
Sofinnova Partners nomme le Dr Chika Yoshinaga Vice President, en charge de l’Asie
- 24/09/2007
- 24/09/2007
- 25/09/2007
-
25/09/2007
VoluBill raise 10.5 Million Euros to fund aggressive growth strategy
-
25/09/2007
VoluBill lève 10,5 Millions d’Euros pour financer une stratégie de croissance agressive
-
24/09/2007
First-in-man milestone reported for the Stentys bifurcated drug-eluting stent
-
25/09/2007
Purple Labs Raises .5 Million USD in Initial Round of Venture Capital Financing
-
29/09/2007
7TM Pharma hires experienced Director of Business Development and Medical Director
- 24/09/2007
-
01/10/2007
Noxxon Pharma appoints Dr. Joachim Kempeni as Chief Medical Officer
- 04/10/2007
- 10/10/2007
- 19/10/2007
-
22/10/2007
Diatos announces the successful completion of Phase I trial for DTS-201, a novel doxorubicin prodrug
- 23/10/2007
- 24/10/2007
- 23/10/2007
- 30/10/2007
-
30/10/2007
Kyocera WIRELESS and Inside Contactless join forces on NFC integration
- 30/10/2007
- 01/11/2007
-
05/11/2007
Inside Contactless empowers new generation NFC payment project with carrier Far EasTone in Taïwan
- 05/11/2007
- 06/11/2007
-
06/11/2007
ABLYNX RAISES €75 MILLION IN SUCCESSFUL IPO - Largest ever biotech IPO on Euronext Brussels
- 12/11/2007
- 23/10/2007
- 23/10/2007
- 07/11/2007
-
09/11/2007
INSIDE Contactless ranked in the Deloitte Technology Fast 50 list for South of France
-
09/11/2007
Noxxon Pharma announces research & development alliance with Roche regarding inflammatory diseases.
- 13/11/2007
- 13/11/2007
-
13/11/2007
DBV Technologies stengthens board of Directors and Scientific Advisory Board
- 13/11/2007
- 14/11/2007
- 15/11/2007
- 05/11/2007
- 12/11/2007
-
16/11/2007
Esmertec reduces debts and increases equity by early conversion of outstanding convertible bonds
-
03/12/2007
Addex and Merck & Co. Collaborate to Develop Drugs for Parkinson’s Disease
- 04/12/2007
-
04/12/2007
Preglem SA announces CHF 36 million Series B funding and new licencing agreement with HRA Pharma
-
27/11/2007
FOVEA Pharmaceuticals Enter Into a Research Collaboration in Ophthalmology With GENZYME Corporation
- 27/11/2007
-
11/12/2007
Nokia Growth Partners leads Series C investment round in INSIDE Contactless
- 12/12/2007
-
13/12/2007
Ascendis Pharma A/S Completes €17.6 Million Series-A Financing
-
16/12/2007
Movistar selects Esmertec’s USSD platform for Latin American operations
-
13/12/2007
Mobile Digital Media Named Exclusive Retail Publisher and Distributor for Atkins™ Carb Counter
-
17/12/2007
Ablynx reports positive phase I results for its anti-thrombotic nanobody®, ALX-0081
- 20/12/2007
-
05/12/2007
SFR adopte la plate-forme de Streamezzo pour optimiser son nouveau portail rich media
-
05/12/2007
SFR adopts Streamezzo's software platform to power new rich media portal
-
10/12/2007
Streamezzo names Alex Middleton General Manager for Americas
- 27/12/2007
- 10/04/2007